Estradiol - Acrux

Drug Profile

Estradiol - Acrux

Alternative Names: Ellavie; Estradiol MDTS®; Estradiol transdermal spray - Acrux; Evamist

Latest Information Update: 02 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acrux
  • Developer Acrux; AMAG Pharmaceuticals
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Vasomotor symptoms

Most Recent Events

  • 01 Dec 2016 Alvogen Pine Brook completes a phase III trial in Atrophic vaginitis in USA (NCT02995694)
  • 01 Apr 2016 Alvogen Pine Brook initiates enrolment in a phase III trial in Atrophic vaginitis in USA (NCT02995694)
  • 12 Nov 2014 Lumara Health has been acquired by AMAG Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top